Bone marrow mesenchymal stem cells (BM-MSCs) are multipotent stem cells that can differentiate into different kinds of mesenchymal cells such as osteoblasts, chondroblasts, and adipocytes. These cells were identified a long time ago and are considered the first discovered source of MSCs. BM-MSC transplantation is used to treat bone disease, myocardial infarction, stroke, and diabetes mellitus. This study aimed to provide a new method for the in vitro primary culture and secondary culture of BM-MSCs that is compliant with good manufacturing practices, for use in clinical applications. Bone marrow was aspirated from the hipbone by using special needles and syringes. Mononuclear cells (MNCs) were isolated from the marrow by using Ficoll-Hypaque gradient centrifugation. These MNCs were cultured in DMEM/F12 medium supplemented with 2.5%, 5%, and 10% activated platelet rich plasma (aPRP) in the experimental groups and 10% FBS in the control group to obtain BM-MSCs. The results showed that aPRP could be replaced with FBS for isolation and proliferation of BM-MSCs. BM-MSCs cultured in both DMEM/F12 medium supplemented with aPRP and DMEM/F12 medium supplemented with FBS exhibited the characteristic phenotype of MSCs, such as being positive for CD44, CD73, CD90, and CD105, and being negative for CD14, CD34, CD45, and HLA-DR.
Introduction
Bone marrow-derived mesenchymal stem cells (BM-MSCs) have long been used in both preclinical and clinical studies. BM-MSCs were first discovered by Friedenstein in 1968 (Friedenstein et al., 1968 . Based on the first demonstration by Friedenstein, these cells were also seen in other tissues such as umbilical cord blood (Pham et al., 2014) , umbilical cord (Leite et al., 2014) , adipose tissue (Van Pham et al., 2013) , dental pulp (Ferro et al., 2014) , placenta (Brooke et al., 2009) , and menstrual blood (de Carvalho Rodrigues et al., 2012) . To confirm which stem cells are MSCs, Dominici et al. (2006) suggested three criteria: plastic adherence when maintained in standard culture conditions, expression of CD105, CD73, and CD90 and non-expression of CD45, CD34, CD14, or CD11b, CD79 alpha, or CD19 and HLA-DR, and successful differentiation into osteoblasts, adipocytes, and chondroblasts in vitro (Dominici et al., 2006) . BM-MSCs are used to pre-clinically treat diseases in animal models of Alzheimer's and Parkinson's diseases (Danielyan et al., 2014; Danielyan et al., 2011) , rheumatoid arthritis (Papadopoulou et al., 2012) , amyotrophic lateral sclerosis (Chan-Il et al., 2013) , diabetes (Ezquer et al., 2009) , etc. They are used clinically in humans to treat idiopathic pulmonary fibrosis (Chambers et al., 2014) , cirrhosis (hepatocellular carcinoma) (Vainshtein et al., 2014) , cirrhotic rats (Li et al., 2013) , autoimmune diseases (Lee et al., 2014) , cartilage disease (Veronesi et al., 2013) , etc.
To increase the number of BM-MSCs, BM-MSCs are subjected to long-term culture in vitro. However, in most studies, MSCs were cultured in media containing xenogeneic additives such as fetal bovine serum (FBS) (Choudhery et al., 2013; Huang et al., 2014; Odabas et al., 2014) . These media are associated with risks such as prion-mediated infections, viral transmission, and adverse immunological reactions. However, serum-free media are commercially available for use in BM-MSC culture. The main limitations of these media are their high cost and complexity. In fact, when grown in serum-free media, BMMSCs hardly adhere to culture-flask surfaces; hence, all culture flasks must be pre-coated with adherent matrixes.
In this study, we established an animal productfree expansion protocol by using autologous activated platelet rich plasma. During the procedure, all components of animal origin, such as trypsin, were not used. Thus, because this protocol is free of animal products, it is safe and feasible for large-scale BM-MSC isolation and expansion for use in clinical applications.
Materials-Methods

Bone Marrow and Peripheral Blood Collection
The project was approved by the local ethics committee. Five donors participated in this study. In total, 20 mL of bone marrow was aspirated from each donor after obtaining informed consent. The collection was performed in accordance with the standards of the local ethics committee. Besides BM samples, 20 mL peripheral blood was also collected from each donor. Both BM and peripheral blood were anticoagulated by using CDPA solution. All samples were immediately transferred to the laboratory.
MNC Isolation and Activated PRP Preparation
Mononuclear cells (NMCs) were isolated from the bone marrow. The BM samples were diluted at a ratio of 1:1 with phosphate-buffered solution (PBS) and then subjected to density centrifugation using Ficoll-Hypaque (1.077 g/mL; Sigma-Aldrich, St Louis, MO, USA). BM samples were centrifuged at 3000 rpm for 30 min. MNCs were collected from the interphase of the centrifuge tube.
The collected MNCs were washed twice with PBS and then used for further experiments.
Peripheral blood samples were used to produce activated PRP (aPRP). ACD anti-coagulated peripheral blood samples were centrifuged in two steps to get PRP.
In the first step, these samples were centrifuged at 500 × g for 5 min to obtain plasma. In the second step, the plasma samples were centrifuged at 800 × g for 10 min to obtain platelet pellets at the bottom of the tubes. To prepare aPRP, a third of the plasma volume and the platelet pellet was collected and re-suspended, following which 100 μL CaCl 2 per 1 mL of PRP was added to activate growth factor release. The samples were then incubated at 37°C for 30 min or until clotting occurred.
Primary Culture
Primary culture was performed as described in a previously published study (Pham et al., 2014) . As a positive control, the mice were also injected with breast cancer cells at a different site. Tumor formation in mice was followed up for three months. In fact, these cells were positive for CD44, CD73, CD90
and CD105 and negative for CD14, CD34, CD45, and HLA-DR. This phenotype also agreed with that reported in previously published studies (Iudicone et al., 2014; Narbona-Carceles et al., 2014; Robey et al., 2014) .
Although culture medium with 10% FBS excellently enhanced cell adherence to the flask surface in a manner similar to that observed in culture medium with 10% PRP during the primary culture, during the secondary culture, PRP efficiently stimulated BM-MSC growth. In fact, at 2.5% PRP concentration in the culture medium, proliferation rates of BM-MSCs in both 2.5% PRP medium and 10% FBS medium were similar. Moreover, their proliferation rates were significantly different between 10% FBS medium and 5% PRP and 10% PRP media.
These results showed that PRP is a rich source of natural human growth factors. Moreover, these growth factors 
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